Molecular basis of hemostatic and thrombotic diseases

Karlyn A Martin, Alice D. Ma, Nigel S. Key

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The coagulation system, composed of cells and soluble protein elements, leads to hemostasis (physiologic blood clotting) at the site of blood vessel injury. Thrombosis refers to the process of excessive clotting that results in adverse cardiovascular events, including myocardial infarction, thrombotic stroke, and venous thromboembolism. Hemostasis is normally regulated by antithrombotic mechanisms that serve to prevent excess clot formation. Disorders of hemostasis or thrombosis can occur when components of the coagulation system are missing or dysfunctional. Hemostatic defects may lead to bleeding via the following mechanisms: (1) deficient thrombin generation on the proper cellular surface due to deficiencies of factor VIII or IX (hemophilia A and B) required for the propagation phase of thrombin generation, deficiencies of factors in the final common pathway of thrombin generation (factors II, V, and X), deficiency of factor XI (required for "over-drive" of coagulation), defect in fibrin polymerization via either deficiencies or abnormalities of fibrinogen, or deficiency of Factor XIII (required for cross linking fibrin); (2) defect in primary hemostasis due to Von Willebrand disease or platelet dysfunction; or (3) abnormal fibrinolysis. Defects in the anticoagulant system lead to thrombosis via the following mechanisms: (1) unopposed or excess generation of thrombin via antithrombin deficiency or prothrombin G20210A mutation and (2) insufficient inactivation of procoagulant proteins via activated protein C resistance (including that due to the factor V Leiden mutation) and deficiencies of protein C or protein S.

Original languageEnglish (US)
Title of host publicationMolecular Pathology
Subtitle of host publicationThe Molecular Basis of Human Disease
PublisherElsevier Inc
Pages277-297
Number of pages21
ISBN (Print)9780128027615
DOIs
StatePublished - Nov 2 2017

Fingerprint

Hemostatics
Hemostasis
Thrombin
Hemophilia B
Thrombosis
Hemophilia A
Fibrin
Factor V Deficiency
Afibrinogenemia
Hypoprothrombinemias
Factor XI
Activated Protein C Resistance
Factor XIII
Factor X
Mutation
Antithrombins
Protein S
Venous Thromboembolism
Prothrombin
Blood Coagulation

Keywords

  • Clotting factors
  • Hemophilia
  • Hemostasis
  • Platelet dysfunction
  • Thrombophilia
  • Thrombosis
  • Thrombotic microangiopathy
  • Von Willebrand disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Martin, K. A., Ma, A. D., & Key, N. S. (2017). Molecular basis of hemostatic and thrombotic diseases. In Molecular Pathology: The Molecular Basis of Human Disease (pp. 277-297). Elsevier Inc. https://doi.org/10.1016/B978-0-12-802761-5.00015-8
Martin, Karlyn A ; Ma, Alice D. ; Key, Nigel S. / Molecular basis of hemostatic and thrombotic diseases. Molecular Pathology: The Molecular Basis of Human Disease. Elsevier Inc, 2017. pp. 277-297
@inbook{35a1996a2926456391cb8a2af22acfb9,
title = "Molecular basis of hemostatic and thrombotic diseases",
abstract = "The coagulation system, composed of cells and soluble protein elements, leads to hemostasis (physiologic blood clotting) at the site of blood vessel injury. Thrombosis refers to the process of excessive clotting that results in adverse cardiovascular events, including myocardial infarction, thrombotic stroke, and venous thromboembolism. Hemostasis is normally regulated by antithrombotic mechanisms that serve to prevent excess clot formation. Disorders of hemostasis or thrombosis can occur when components of the coagulation system are missing or dysfunctional. Hemostatic defects may lead to bleeding via the following mechanisms: (1) deficient thrombin generation on the proper cellular surface due to deficiencies of factor VIII or IX (hemophilia A and B) required for the propagation phase of thrombin generation, deficiencies of factors in the final common pathway of thrombin generation (factors II, V, and X), deficiency of factor XI (required for {"}over-drive{"} of coagulation), defect in fibrin polymerization via either deficiencies or abnormalities of fibrinogen, or deficiency of Factor XIII (required for cross linking fibrin); (2) defect in primary hemostasis due to Von Willebrand disease or platelet dysfunction; or (3) abnormal fibrinolysis. Defects in the anticoagulant system lead to thrombosis via the following mechanisms: (1) unopposed or excess generation of thrombin via antithrombin deficiency or prothrombin G20210A mutation and (2) insufficient inactivation of procoagulant proteins via activated protein C resistance (including that due to the factor V Leiden mutation) and deficiencies of protein C or protein S.",
keywords = "Clotting factors, Hemophilia, Hemostasis, Platelet dysfunction, Thrombophilia, Thrombosis, Thrombotic microangiopathy, Von Willebrand disease",
author = "Martin, {Karlyn A} and Ma, {Alice D.} and Key, {Nigel S.}",
year = "2017",
month = "11",
day = "2",
doi = "10.1016/B978-0-12-802761-5.00015-8",
language = "English (US)",
isbn = "9780128027615",
pages = "277--297",
booktitle = "Molecular Pathology",
publisher = "Elsevier Inc",

}

Martin, KA, Ma, AD & Key, NS 2017, Molecular basis of hemostatic and thrombotic diseases. in Molecular Pathology: The Molecular Basis of Human Disease. Elsevier Inc, pp. 277-297. https://doi.org/10.1016/B978-0-12-802761-5.00015-8

Molecular basis of hemostatic and thrombotic diseases. / Martin, Karlyn A; Ma, Alice D.; Key, Nigel S.

Molecular Pathology: The Molecular Basis of Human Disease. Elsevier Inc, 2017. p. 277-297.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Molecular basis of hemostatic and thrombotic diseases

AU - Martin, Karlyn A

AU - Ma, Alice D.

AU - Key, Nigel S.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - The coagulation system, composed of cells and soluble protein elements, leads to hemostasis (physiologic blood clotting) at the site of blood vessel injury. Thrombosis refers to the process of excessive clotting that results in adverse cardiovascular events, including myocardial infarction, thrombotic stroke, and venous thromboembolism. Hemostasis is normally regulated by antithrombotic mechanisms that serve to prevent excess clot formation. Disorders of hemostasis or thrombosis can occur when components of the coagulation system are missing or dysfunctional. Hemostatic defects may lead to bleeding via the following mechanisms: (1) deficient thrombin generation on the proper cellular surface due to deficiencies of factor VIII or IX (hemophilia A and B) required for the propagation phase of thrombin generation, deficiencies of factors in the final common pathway of thrombin generation (factors II, V, and X), deficiency of factor XI (required for "over-drive" of coagulation), defect in fibrin polymerization via either deficiencies or abnormalities of fibrinogen, or deficiency of Factor XIII (required for cross linking fibrin); (2) defect in primary hemostasis due to Von Willebrand disease or platelet dysfunction; or (3) abnormal fibrinolysis. Defects in the anticoagulant system lead to thrombosis via the following mechanisms: (1) unopposed or excess generation of thrombin via antithrombin deficiency or prothrombin G20210A mutation and (2) insufficient inactivation of procoagulant proteins via activated protein C resistance (including that due to the factor V Leiden mutation) and deficiencies of protein C or protein S.

AB - The coagulation system, composed of cells and soluble protein elements, leads to hemostasis (physiologic blood clotting) at the site of blood vessel injury. Thrombosis refers to the process of excessive clotting that results in adverse cardiovascular events, including myocardial infarction, thrombotic stroke, and venous thromboembolism. Hemostasis is normally regulated by antithrombotic mechanisms that serve to prevent excess clot formation. Disorders of hemostasis or thrombosis can occur when components of the coagulation system are missing or dysfunctional. Hemostatic defects may lead to bleeding via the following mechanisms: (1) deficient thrombin generation on the proper cellular surface due to deficiencies of factor VIII or IX (hemophilia A and B) required for the propagation phase of thrombin generation, deficiencies of factors in the final common pathway of thrombin generation (factors II, V, and X), deficiency of factor XI (required for "over-drive" of coagulation), defect in fibrin polymerization via either deficiencies or abnormalities of fibrinogen, or deficiency of Factor XIII (required for cross linking fibrin); (2) defect in primary hemostasis due to Von Willebrand disease or platelet dysfunction; or (3) abnormal fibrinolysis. Defects in the anticoagulant system lead to thrombosis via the following mechanisms: (1) unopposed or excess generation of thrombin via antithrombin deficiency or prothrombin G20210A mutation and (2) insufficient inactivation of procoagulant proteins via activated protein C resistance (including that due to the factor V Leiden mutation) and deficiencies of protein C or protein S.

KW - Clotting factors

KW - Hemophilia

KW - Hemostasis

KW - Platelet dysfunction

KW - Thrombophilia

KW - Thrombosis

KW - Thrombotic microangiopathy

KW - Von Willebrand disease

UR - http://www.scopus.com/inward/record.url?scp=85054296682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054296682&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802761-5.00015-8

DO - 10.1016/B978-0-12-802761-5.00015-8

M3 - Chapter

SN - 9780128027615

SP - 277

EP - 297

BT - Molecular Pathology

PB - Elsevier Inc

ER -

Martin KA, Ma AD, Key NS. Molecular basis of hemostatic and thrombotic diseases. In Molecular Pathology: The Molecular Basis of Human Disease. Elsevier Inc. 2017. p. 277-297 https://doi.org/10.1016/B978-0-12-802761-5.00015-8